Tags

Type your tag names separated by a space and hit enter

Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.
Appl Immunohistochem Mol Morphol. 2020 01; 28(1):42-48.AI

Abstract

AIM

The categorization of endometrial carcinomas into endometrioid and serous categories has prognostic implications but many-a-times, it is difficult to categorize based solely on morphology. The present study was conducted to determine an appropriate immunohistochemical panel to distinguish grade 3 endometrioid carcinoma from serous carcinoma.

EXPERIMENTAL DESIGN

This study was a retrospective and a prospective study including 63 cases of endometrial carcinoma diagnosed on morphology as either grade 3 endometrioid (n=29) or serous endometrial carcinomas (n=34). Immunohistochemistry (IHC) was performed using tissue microarrays for 8 immunomarkers on 60 cases.

RESULTS

The mean age of presentation was not significantly different for both types of carcinomas and the most common presentation was postmenopausal bleeding (93% of the total cases, P=0.66). Obesity (P=0.038), lymph nodal involvement (P=0.044), and stage at presentation (P=0.042) were found to be significantly different among the 2 types of carcinomas. Estrogen and progesterone receptor (ER, PR) positivity was more common (47.6% and 28.2%, respectively) in endometrioid carcinomas as compared with serous. Mutation type (diffuse or null) p53 staining was a powerful predictor of serous carcinomas. IMP3 and p16 were found to be positive in most cases of serous carcinoma (64.1% and 79.5%, respectively). Vimentin and β-catenin were found to be of limited utility. On the basis of IHC, 21 cases could be categorized as grade 3 endometrioid carcinomas and 39 as type 2 carcinomas (serous and clear cell carcinoma).

CONCLUSIONS

The most appropriate IHC panel to differentiate endometrioid and serous endometrial carcinomas includes ER, PR, IMP3, p53, and p16.

Authors+Show Affiliations

Departments of Cytology and Gynecological Pathology.Departments of Cytology and Gynecological Pathology.Departments of Cytology and Gynecological Pathology.Departments of Cytology and Gynecological Pathology.Radiotherapy.Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31815745

Citation

Zaidi, Ariba, et al. "Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma." Applied Immunohistochemistry & Molecular Morphology : AIMM, vol. 28, no. 1, 2020, pp. 42-48.
Zaidi A, Gupta P, Gupta N, et al. Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. Appl Immunohistochem Mol Morphol. 2020;28(1):42-48.
Zaidi, A., Gupta, P., Gupta, N., Rajwanshi, A., Rai, B., & Gainder, S. (2020). Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. Applied Immunohistochemistry & Molecular Morphology : AIMM, 28(1), 42-48. https://doi.org/10.1097/PAI.0000000000000720
Zaidi A, et al. Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. Appl Immunohistochem Mol Morphol. 2020;28(1):42-48. PubMed PMID: 31815745.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma. AU - Zaidi,Ariba, AU - Gupta,Parikshaa, AU - Gupta,Nalini, AU - Rajwanshi,Arvind, AU - Rai,Bhavana, AU - Gainder,Shalini, PY - 2019/12/10/entrez PY - 2019/12/10/pubmed PY - 2019/12/10/medline SP - 42 EP - 48 JF - Applied immunohistochemistry & molecular morphology : AIMM JO - Appl. Immunohistochem. Mol. Morphol. VL - 28 IS - 1 N2 - AIM: The categorization of endometrial carcinomas into endometrioid and serous categories has prognostic implications but many-a-times, it is difficult to categorize based solely on morphology. The present study was conducted to determine an appropriate immunohistochemical panel to distinguish grade 3 endometrioid carcinoma from serous carcinoma. EXPERIMENTAL DESIGN: This study was a retrospective and a prospective study including 63 cases of endometrial carcinoma diagnosed on morphology as either grade 3 endometrioid (n=29) or serous endometrial carcinomas (n=34). Immunohistochemistry (IHC) was performed using tissue microarrays for 8 immunomarkers on 60 cases. RESULTS: The mean age of presentation was not significantly different for both types of carcinomas and the most common presentation was postmenopausal bleeding (93% of the total cases, P=0.66). Obesity (P=0.038), lymph nodal involvement (P=0.044), and stage at presentation (P=0.042) were found to be significantly different among the 2 types of carcinomas. Estrogen and progesterone receptor (ER, PR) positivity was more common (47.6% and 28.2%, respectively) in endometrioid carcinomas as compared with serous. Mutation type (diffuse or null) p53 staining was a powerful predictor of serous carcinomas. IMP3 and p16 were found to be positive in most cases of serous carcinoma (64.1% and 79.5%, respectively). Vimentin and β-catenin were found to be of limited utility. On the basis of IHC, 21 cases could be categorized as grade 3 endometrioid carcinomas and 39 as type 2 carcinomas (serous and clear cell carcinoma). CONCLUSIONS: The most appropriate IHC panel to differentiate endometrioid and serous endometrial carcinomas includes ER, PR, IMP3, p53, and p16. SN - 1533-4058 UR - https://www.unboundmedicine.com/medline/citation/31815745/Role_of_Immunohistochemistry_to_Distinguish_Grade_3_Endometrioid_Carcinoma_and_Uterine_Serous_Carcinoma_ L2 - https://doi.org/10.1097/PAI.0000000000000720 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.